Literature DB >> 15982856

What does the PANSS mean?

Stefan Leucht1, John M Kane, Werner Kissling, Johannes Hamann, Eva Etschel, Rolf R Engel.   

Abstract

OBJECTIVE: Despite the frequent use of the Positive and Negative Syndrome Scale (PANSS) for rating the symptoms of schizophrenia, the clinical meaning of its total score and of the cut-offs that are used to define treatment response (e.g. at least 20% or 50% reduction of the baseline score) are as yet unclear. We therefore compared the PANSS with simultaneous ratings of Clinical Global Impressions (CGI).
METHOD: PANSS and CGI ratings at baseline (n = 4091), and after one, two, four and six weeks of treatment taken from a pooled database of seven pivotal, multi-center antipsychotic drug trials on olanzapine or amisulpride in patients with exacerbations of schizophrenia were compared using equipercentile linking.
RESULTS: Being considered "mildly ill" according to the CGI approximately corresponded to a PANSS total score of 58, "moderately ill" to a PANSS of 75, "markedly ill" to a PANSS of 95 and severely ill to a PANSS of 116. To be "minimally improved" according to the CGI score was associated with a mean percentage PANSS reduction of 19%, 23%, 26% and 28% at weeks 1, 2, 4 and 6, respectively. The corresponding figures for a CGI rating "much improved" were 40%, 45%, 51% and 53%.
CONCLUSIONS: The results provide a better framework for understanding the clinical meaning of the PANSS total score in drug trials of schizophrenia patients with acute exacerbations. Such studies may ideally use at least a 50% reduction from baseline cut-off to define response rather than lower thresholds. In treatment resistant populations, however, even a small improvement can be important, so that a 25% cut-off might be appropriate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982856     DOI: 10.1016/j.schres.2005.04.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  320 in total

Review 1.  Zotepine versus other atypical antipsychotics for schizophrenia.

Authors:  Selvizhi Subramanian; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Werner Kissling; Stefan Leucht; Katja Komossa
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

3.  The interrelation of needs and quality of life in first-episode schizophrenia.

Authors:  Karin Landolt; Wulf Rössler; Tom Burns; Vladeta Ajdacic-Gross; Silvana Galderisi; Jan Libiger; Dieter Naber; Eske M Derks; René S Kahn; W Wolfgang Fleischhacker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-24       Impact factor: 5.270

Review 4.  Cognitive behavioural therapy (brief versus standard duration) for schizophrenia.

Authors:  Farooq Naeem; Saeed Farooq; David Kingdon
Journal:  Cochrane Database Syst Rev       Date:  2015-10-21

5.  [Considerations about the efficacy of psychopharmacological drugs].

Authors:  S Leucht; S Heres; J M Davis
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

Review 6.  Supportive therapy for schizophrenia.

Authors:  Lucy A Buckley; Nicola Maayan; Karla Soares-Weiser; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-04-14

7.  Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia.

Authors:  Sophia Mueller; Danhong Wang; Ruiqi Pan; Daphne J Holt; Hesheng Liu
Journal:  JAMA Psychiatry       Date:  2015-06       Impact factor: 21.596

Review 8.  Crisis intervention for people with severe mental illnesses.

Authors:  Suzanne Murphy; Claire B Irving; Clive E Adams; Ron Driver
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

9.  Minimal Clinically Important Differences (MCID) in Assessing Outcomes of Post-Traumatic Stress Disorder.

Authors:  Elina A Stefanovics; Robert A Rosenheck; Karen M Jones; Grant Huang; John H Krystal
Journal:  Psychiatr Q       Date:  2018-03

10.  The latent structure of psychiatric symptoms across mental disorders as measured with the PANSS and BPRS-18.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Kevin J Grimm; Stephen J Tueller; Kiersten L Johnson; Brian G Sellers; Marvin S Swartz
Journal:  Psychiatry Res       Date:  2016-08-09       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.